Grifols, S.A. (GRFS): Price and Financial Metrics

Grifols, S.A. (GRFS)

Today's Latest Price: $18.20 USD

0.83 (-4.36%)

Updated Oct 22 4:00pm

Add GRFS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

GRFS Stock Summary

  • GRFS has a market capitalization of $13,084,169,899 -- more than approximately 87.16% of US stocks.
  • For GRFS, its debt to operating expenses ratio is greater than that reported by 84.04% of US equities we're observing.
  • The volatility of Grifols SA's share price is greater than that of only 15.96% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Grifols SA, a group of peers worth examining would be CAE, EMN, MYL, EBIX, and ITGR.
  • Visit GRFS's SEC page to see the company's official filings. To visit the company's web site, go to

GRFS Stock Price Chart Interactive Chart >

Price chart for GRFS

GRFS Price/Volume Stats

Current price $18.20 52-week high $25.73
Prev. close $19.03 52-week low $13.40
Day low $18.08 Volume 2,392,600
Day high $18.80 Avg. volume 1,254,367
50-day MA $17.14 Dividend yield 0.89%
200-day MA $19.72 Market Cap 12.51B

Grifols, S.A. (GRFS) Company Bio

Grifols, S.A. develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation, and reagents for use in hospitals and clinics. The company operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The company was founded in 1940 and is based in Barcelona, Spain.

GRFS Latest News Stream

Event/Time News Detail
Loading, please wait...

GRFS Latest Social Stream

Loading social stream, please wait...

View Full GRFS Social Stream

Latest GRFS News From Around the Web

Below are the latest news stories about Grifols SA that investors may wish to consider to help them evaluate GRFS as an investment opportunity.

Plasma Fractionation Market to Grow at Rapid Pace by 2025 With Major Key Players : Grifols, CSL, Kedrion, BPL

The Plasma Fractionation market 2020 report includes thorough gathering of the quantitative analysis of the industry in order to assist players to grow in the market. Perceptions on specific revenue figures generated are also given in the report. This

OpenPR | October 2, 2020

Worldwide Plasma Fractionation Industry to 2025 - Featuring CSL, Grifols & Shire Among Others

DUBLIN, Oct. 1, 2020 /PRNewswire/ -- The "Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology, Pulmonology), End User (Hospitals & Clinics) - Global Forecast…

PR Newswire | October 1, 2020

Intravenous Immunoglobulin (IVIg) Market Foreseen to Draw a Promising Growth of $10.8 Billion by 2025 | Baxter, Grifols, CSL, Octapharma, Biotest, Kedrion, CNBG

Global Intravenous Immunoglobulin (IVIg) Market Synopsis: The Intravenous Immunoglobulin (IVIg) Market has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Intravenous Immunoglobulin (IVIg) market size to maintain the average annual growth rate of

OpenPR | September 29, 2020

Worldwide Therapeutic Drug Monitoring Industry to 2025 - Players Include Biomerieux, Theradiag & Grifols Among Others -

DUBLIN--(BUSINESS WIRE)--The "Therapeutic Drug Monitoring Market by Product (Equipment (Immunoassay Analyzers), Consumables), Technology (Immunoassays, Chromatography-MS), Class of Drugs (Antibiotic Drugs, Bronchodilator Drugs), End User - Global Forecast to 2025" report has been added to's offering. The global therapeutic drug monitoring market is projected to reach USD 2.0 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.9% from 2020 to 2025. The growth of t

Business Wire | September 23, 2020

Worldwide Blood Collection Industry to 2025 - Featuring Terumo BCT, Fresenius Kabi & Grifols Among Others

DUBLIN , Sept. 21, 2020 /PRNewswire/ -- The "Blood Collection Market by Product (Tubes (Plasma (EDTA, Heparin, Glucose), Serum), Blood Bags, Monitors, Needles), Method (Manual, Automated), Application (Diagnostic, Therapeutic), End User (Hospitals & ASCs, Blood Banks, Labs) - Global Forecast to 2025" report has been added to's offering. The global blood collection devices market is projected to reach USD 6.47 billion by 2025 from USD 4.83 billion in 2020, at a CAGR of 6.0% between 2020 and 2025. The growth of this market is majorly driven by factors such as the increasing incidence of infectious diseases, the rising number of accidents & trauma cases, the emergence of liquid biopsy tests, and a demand for blood donations and blood components. However, complexities...

Benzinga | September 21, 2020

Read More 'GRFS' Stories Here

GRFS Price Returns

1-mo 12.00%
3-mo -1.78%
6-mo -10.08%
1-year -12.22%
3-year -10.20%
5-year 13.72%
YTD -21.85%
2019 28.71%
2018 -17.77%
2017 44.48%
2016 0.90%
2015 -2.72%

GRFS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GRFS Dividend History

Continue Researching GRFS

Here are a few links from around the web to help you further your research on Grifols SA's stock as an investment opportunity:

Grifols SA (GRFS) Stock Price | Nasdaq
Grifols SA (GRFS) Stock Quote, History and News - Yahoo Finance
Grifols SA (GRFS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7667 seconds.